Sequential treatment with aurora B inhibitors enhances cisplatin-mediated apoptosis via c-Myc
Authors:
- 21 November 2014
- journal article
- Published by Springer Nature in Journal of Molecular Medicine
- Vol. 93 (4) , 427-438
Abstract
Platinum compound such as cisplatin is the first-line chemotherapy of choice in most patients with ovarian carcinoma. However, patients with inherent or acquired cisplatin resistance often experience relapse. Therefore, novel therapies are urgently required to treat drug-resistant ovarian carcinoma. Here, we showed that compared to the non-functional traditional simultaneous treatment, sequential combination of Aurora B inhibitors followed by cisplatin synergistically enhanced apoptotic response in cisplatin-resistant OVCAR-8 cells. This effect was accompanied by the induction of polyploidy in a c-Myc-dependent manner, as c-Myc knockdown reduced the efficacy of the combination by suppressing the expression of Aurora B and impairing cellular response to Aurora B inhibitor, as indicated by the decreased polyploidy and hyperphosphorylation of histone H1. In c-Myc-deficient SKOV3 cells, c-Myc overexpression restored Aurora B expression, induced polyploidy after inhibition of Aurora B, and sensitized cells to this combination therapy. Thus, our report reveals for the first time that sequential treatment of Aurora B inhibitors and cisplatin is essential to inhibit ovarian carcinoma by inducing polyploidy and downregulating c-Myc and that c-Myc is identified as a predictive biomarker to select cells responsive to chemotherapeutical combinations targeting Aurora B. Collectively, these studies provide novel approaches to overcoming cisplatin chemotherapy resistance in ovarian cancer. Pretreatment of Aurora B inhibitors augment apoptotic effects of cisplatin. The synergy of Aurora B inhibitor with cisplatin is dependent on c-Myc expression. c-Myc-dependent induction of polyploidy sensitizes cells to cisplatin.Keywords
This publication has 34 references indexed in Scilit:
- Involvement of mitogen‐activated protein kinase in signal transducer and activator of transcription‐1 mediated differentiation induced by bortezomib in acute myeloid leukemia cellsMolecular Carcinogenesis, 2011
- ZM447439, the Aurora kinase B inhibitor, suppresses the growth of cervical cancer SiHa cells and enhances the chemosensitivity to cisplatinJournal of Obstetrics and Gynaecology Research, 2010
- Aurora kinases A and B are up-regulated by Myc and are essential for maintenance of the malignant stateBlood, 2010
- Antineoplastic effects of an Aurora B kinase inhibitor in breast cancerMolecular Cancer, 2010
- Overexpression of Aurora B is associated with poor prognosis in epithelial ovarian cancer patientsVirchows Archiv, 2009
- Prognostic relevance of c-MYC gene amplification and polysomy for chromosome 8 in suboptimally-resected, advanced stage epithelial ovarian cancers: A Gynecologic Oncology Group studyGynecologic Oncology, 2009
- The Topoisomerase I Poison CPT-11 Enhances the Effect of the Aurora B Kinase Inhibitor AZD1152 both In vitro and In vivoClinical Cancer Research, 2009
- The Aurora kinase family in cell division and cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2008
- Limiting the Proliferation of Polyploid CellsCell, 2007
- Ovarian cancer: strategies for overcoming resistance to chemotherapyNature Reviews Cancer, 2003